Precision Medicine in High-Burden Cancers: Molecular Innovation Amid Persistent Access and Outcome Disparities

The Precision Oncology Paradox

Precision medicine has substantially reshaped care for several high-burden malignancies—lung, breast, colorectal, prostate, liver, and gastric cancers—although the magnitude of impact varies markedly by tumor type, and clinical benefits remain stratified by socioeconomic status, geography, and health system capacity. While regulatory approvals for targeted therapies have accelerated, the translation from molecular discovery to equitable patient access faces critical bottlenecks: inadequate biomarker testing infrastructure, fragmented insurance coverage, and persistent outcome disparities that widen even as overall survival improves23. This review synthesizes current evidence on the precision medicine landscape across major cancers, interrogating the gap between therapeutic innovation and real-world implementation.

Molecular Landscape and Therapeutic Maturity Across Cancer Types

The precision oncology ecosystem demonstrates marked heterogeneity in target diversity and drug availability across tumor types. Non-small cell lung cancer (NSCLC) is among the most molecularly segmented indications, with approved targeted therapies (often region-dependent) spanning EGFR (e.g., lazertinib; in China, rilertinib), ALK (e.g., ceritinib), ROS1/NTRK (entrectinib), MET (tepotinib, savolitinib), BRAF V600E (dabrafenib + trametinib; encorafenib + binimetinib), KRAS G12C (e.g., sotorasib), and HER2-mutant disease (trastuzumab deruxtecan), alongside robust immunotherapy options14. In Q1 2026, the FDA granted accelerated approval to zongertinib, a first-in-class HER2 inhibitor for advanced HER2-mutant non-squamous NSCLC, expanding options for this previously underserved molecular subset2225.

Breast cancer demonstrates comparable therapeutic depth, anchored in HER2-directed agents (trastuzumab biosimilars, pertuzumab, tucatinib, trastuzumab deruxtecan), endocrine therapies for hormone receptor-positive disease (fulvestrant, tamoxifen, anastrozole), and emerging selective estrogen receptor degraders (SERDs) including vepdegestrant, camizestrant, and palazestrant advancing through Phase III trials14. The PI3K/AKT/mTOR axis has yielded approved agents such as capivasertib and everolimus, with additional combinations under investigation14.

Colorectal cancer (CRC) precision medicine centers on EGFR inhibition for RAS wild-type disease (e.g., cetuximab, panitumumab), BRAF V600E–directed combinations (e.g., encorafenib-based), and HER2-directed strategies (e.g., trastuzumab- or tucatinib-based regimens), while KRAS G12C inhibitors (e.g., sotorasib with EGFR antibodies) are in late-phase development; specific indications and approval status are region-dependent1422. Prostate cancer remains dominated by androgen receptor pathway manipulation (enzalutamide, leuprolide, relugolix) and PARP inhibition (rucaparib), with AKT inhibitors (capivasertib) and novel steroidogenesis blockers (opevesostat) in late-stage development14.

In contrast, hepatic and gastric cancers exhibit narrower precision portfolios.Liver cancer (primarily HCC) is among indications where immune checkpoint inhibitors have become core options, particularly in combination regimens. Region‑dependent approvals include, for example, camrelizumab‑, sintilimab‑, and tislelizumab‑based therapies in China; and, in many Western markets, PD‑L1 + anti‑VEGF (e.g., atezolizumab + bevacizumab) or CTLA‑4–based combinations (e.g., nivolumab + ipilimumab, durvalumab + tremelimumab). Exact labels and lines of therapy differ across regions and over time.14. Gastric cancer demonstrates emerging HER2 (trastuzumab biosimilars, trastuzumab deruxtecan) and FGFR2b targeting (bemarituzumab in Phase III), alongside immunotherapy combinations1422. Notably, the European Medicines Agency issued a positive opinion for durvalumab in gastric/gastroesophageal junction cancers in January 2026, while the niraparib/abiraterone combination received EMA approval for prostate cancer the same month22.

Biomarker Testing as the Foundational Barrier

Despite robust molecular characterization and expanding therapeutic options, access to precision oncology hinges on biomarker testing—a prerequisite that remains severely underutilized globally. Analysis of 11,415 patients with CRC, NSCLC, or prostate cancer from the NIH All of Us Research Program revealed that only 2.4% had documented biomarker testing, with substantial variation by cancer type: NSCLC (6.2%), CRC (2.1%), and prostate cancer (0.8%)15. Even in a Medicaid-based cohort study of 3,845 metastatic lung cancer patients (2017–2019), only 57% had evidence of any biomarker testing, and next-generation sequencing (NGS)-based comprehensive testing was documented in merely 4.3%1.

Socioeconomic factors significantly predict testing uptake independent of clinical indication. Unemployment was associated with higher odds of testing (odds ratio 1.68; 95% CI 1.06–2.66), while college education showed marginal association (OR 1.48; 95% CI 0.95–2.30)15. Cancer-specific patterns emerged: NSCLC testing was predicted by education (OR 1.70), CRC testing by unemployment (OR 2.44), higher income (OR 1.90), and smoking history15. Biomarker testing was positively associated with targeted therapy use (OR 1.69, p=0.005), underscoring its critical gatekeeping role1.

The European Society for Medical Oncology (ESMO) Precision Medicine Working Group updated recommendations in 2024, advocating routine tumor NGS for non-squamous NSCLC, prostate, colorectal, cholangiocarcinoma, and ovarian cancers, with expansion to advanced breast cancer and rare tumors8. However, real-world implementation lags profoundly: in Brazil's public health system, 80% of early-stage NSCLC patients and 32% of advanced-stage patients lacked access to genomic testing12. Financial barriers, geographic disparities in laboratory capacity, limited health literacy, and insufficient oncologist familiarity with biomarker-driven paradigms collectively result in significantly lower testing rates among Black, Hispanic, low-income, and Medicare/Medicaid populations181920.

Regional Access Disparities and Reimbursement Fragmentation

Regulatory approval does not guarantee therapeutic access. In the United States, the Centers for Medicare & Medicaid Services (CMS) Local Coverage Determination for genetic testing in oncology, effective April 24, 2025, establishes reimbursement frameworks but restricts coverage for multiple molecular tests citing insufficient clinical utility evidence16. Commercial insurers and Medicaid plans demonstrate inconsistent coverage, with prior authorization requirements adding administrative burden and time delays particularly problematic in advanced cancer settings17. In November 2025, H.R. 6320, the Improving Medicaid Precision and Cancer Test Act, was introduced specifically to mandate lung cancer biomarker testing coverage under Medicaid, reflecting recognition of coverage gaps as access barriers21. However, state-level policy volatility persists: despite New York enacting biomarker testing coverage legislation in 2023, a 2026 budget proposal threatened rollback27.

European reimbursement reveals dramatic within-region heterogeneity despite harmonized regulatory pathways. Analysis of EMA-approved novel cancer medicines demonstrated reimbursement rates ranging from 0% in Malta to 96% in Germany, with approval timelines spanning less than 100 days in some jurisdictions to substantially longer periods elsewhere23. Health technology assessment (HTA) body decisions across NICE (UK), IQWiG (Germany), HAS (France), SMC (Scotland), ZIN (Netherlands), and NCPE (Ireland) for 22 targeted therapies and 7 immunotherapies in NSCLC revealed inconsistent evidence standards: NICE and SMC demonstrated highest alignment via managed access agreements, while IQWiG and HAS imposed stricter requirements for immature survival data28. Early access schemes function as essential bridges in France, Italy, and Spain, where formal reimbursement processes are protracted29. Companion diagnostic reimbursement remains fragmented, with five of eight studied countries requiring HTA for companion diagnostics, creating critical bottlenecks where approved targeted therapies remain inaccessible because corresponding diagnostic tests lack coverage31.

China's healthcare system operates via the National Reimbursement Drug List (NRDL), which as of April 2026 includes approximately 270 cancer drugs following a January 2026 update adding 36 antitumor agents24. HTA-based price negotiations have achieved dramatic cost reductions: median daily costs for anticancer therapies decreased from $87.6 (2017) to $39.7 (2020), with sintilimab (China's first PD-1 inhibitor) achieving 64% price reduction upon NRDL listing30. However, no statistically significant correlation was observed between negotiated costs and clinical benefits, raising value-based pricing concerns30. A commercial insurance innovative drug list launched in December 2025 includes 19 therapies beyond basic medical insurance affordability, such as CAR-T therapy previously priced over 1 million yuan per infusion, yet hospital-level hesitancy due to limited real-world evidence creates implementation barriers24.

Patient Outcome Inequalities: Survival Gains Concentrated Among Affluent Populations

While precision medicine has improved outcomes broadly, survival gains have accrued disproportionately to higher-income populations. Longitudinal SEER analysis (2004–2018) of 1,875,281 patients across eight cancer types revealed that Black patients demonstrated the lowest cancer-specific survival in breast, prostate, ovarian, colon, liver, lung, and pancreatic cancers2. Although Black patients experienced the greatest survival improvement from 2009–2018 in breast, ovarian, colorectal, liver, lung, and pancreatic cancer, their cancer-specific survival from 2014–2018 remained lower than White patients from 2004–2008 in breast, ovarian, and prostate cancers, even after controlling for income, age, and stage2. Socioeconomic disparities widened: high-income patients achieved greater survival improvements than low- and middle-income groups in most cancers except breast and liver2.

In South Korea, a high-income country with universal healthcare, comparison of the lowest-income group (Medical Aid beneficiaries) to the highest-income group yielded hazard ratios for mortality of 1.72 (stomach), 1.60 (colorectal), 1.51 (liver), 1.56 (lung), 2.19 (breast), and 1.65 (cervical cancer)9. The breast cancer disparity was most pronounced—paradoxically the disease where precision medicine has advanced most—suggesting that socioeconomic factors create barriers to accessing precision therapies even in universal healthcare systems9. Longitudinal comparison (2002–2006 vs. 2014–2018) revealed widening income disparities for lung (slope index of inequality 17.5), liver (15.1), and stomach cancer (13.9)10.

Analysis of the National Cancer Database (2010–2019) for 2,927,191 patients revealed that minority-serving hospitals had significantly lower odds of delivering definitive therapy across breast (adjusted OR 0.83), prostate (OR 0.69), NSCLC (OR 0.73), and colon cancer (OR 0.81), with no significant site-of-care–race interaction, indicating that disparities affect all races treated at these institutions7. Equalizing treatment rates could result in 5,719 additional patients receiving definitive treatment over a decade7.

Cross-Cancer Implications and Future Directions

NSCLC and breast cancer exhibit the most mature precision ecosystems, with multi-target segmentation and global approval distribution. Colorectal and prostate cancers demonstrate meaningful but narrower precision options, with late-stage programs poised to expand access in defined biomarker subsets. Gastric and hepatic cancers remain less diversified, with regionally uneven progress—particularly strong immunotherapy adoption in China but limited targetable segments in Western markets14.

Clinicians must prioritize comprehensive molecular profiling in diseases where multiple targets dictate therapy, recognizing that testing infrastructure limitations—not biological constraints—drive access disparities. Health systems and policymakers must address cross-region regulatory gaps delaying access to validated targets, expand trial participation capacity in under-resourced tumor types, and mandate standardized biomarker testing coverage. Without coordinated intervention across payers, healthcare systems, and policy frameworks to universalize biomarker testing, transparent reimbursement, and infrastructure investment in underserved regions, precision medicine risks becoming a tool of inequality rather than equity320.